Mirum Pharmaceuticals, Inc. MIRM

MIRM Company Overview

Mirum Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare pediatric liver diseases. The company operates within the biotechnology and specialty pharmaceuticals industry, with an emphasis on cholestatic liver disorders that have limited or no approved treatment options. Mirum’s business model centers on developing bile acid modulation therapies designed to address the underlying drivers of these rare conditions rather than only managing symptoms.

The company’s primary revenue drivers are its approved therapeutics Livmarli (maralixibat) and Bylvay (odevixibat), both indicated for rare cholestatic liver diseases. Mirum primarily serves pediatric and specialty hepatology markets, working closely with specialized physicians and treatment centers. Founded in 2018 and headquartered in the United States, Mirum evolved rapidly from a development-stage company to a commercial organization following regulatory approvals and the strategic acquisition of Albireo Pharma, which significantly expanded its product portfolio and global reach.